ArticleCells2026
Interleukin-1 Receptor Antagonist (IL-1RA) Mediates Age-Dependent Immunoregulation of Adipose-Derived Stem Cells via Macrophage Polarization.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study aimed to clarify whether interleukin-1 receptor antagonist (IL-1RA) mediates the age-dependent immunomodulatory capacity of adipose-derived stem cells (ASCs) via regulating macrophage polarization. ASCs from young (Y-ASCs) and aged (O-ASCs) C57BL/6 mice were isolated. IL-1RA, which was identified as an age-sensitive candidate through integrated transcriptomic and proteomic screening in our prior publication, was validated by qPCR, immunofluorescence, and ELISA. RAW264.7 macrophages were polarized and co-cultured with ASCs or treated with recombinant IL-1RA; IL-1RA in Y-ASCs was silenced by siRNA (82.3 ± 5.1% knockdown efficiency). The results showed Y-ASCs had 2.1-fold higher IL-1RA mRNA and significantly higher protein secretion than O-ASCs (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.